Dr. Squatrito is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5900 Lake Wright Dr
Norfolk, VA 23502Phone+1 757-466-8683Fax+1 757-466-0250
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Gynecologic Oncology, 1992 - 1995
Penn State Milton S Hershey Medical CenterResidency, Obstetrics and Gynecology, 1988 - 1992
Virginia Commonwealth University School of MedicineClass of 1988
Certifications & Licensure
VA State Medical License 1997 - 2026
IA State Medical License 1992 - 1998
VT State Medical License 1995 - 1998
PA State Medical License 1990 - 1992- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
- BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer Start of enrollment: 2013 Feb 01
Publications & Presentations
PubMed
- 30 citationsComparison of a Novel Redox Dye Cell Growth Assay to the ATP Bioluminescence AssayRobert C. Squatrito, Joseph P. Connor, Richard E. Buller
Gynecologic Oncology. 1995-07-01 - 23 citationsEvaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in miceTurgut Alagoz, Richard E. Buller, Barrie Anderson, L B S Kristina Terrell, Robert C. Squatrito
Cancer. 1995-05-01 - 22 citationsPhase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.Angeles Alvarez Secord, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito
Gynecologic Oncology. 2019-06-01
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
